Evommune, Inc.

NYSE:EVMN

Biotechnology

Healthcare
$6.88 -0.82%

-$0.17 today

Market cap
$284.49M
Beta
0.10
P/E (TTM)
-9.1
EPS (TTM)
-$2.26
52W Low $13.89High $33.20

Volume 0.60M

Average 0.38M

EVMN Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Evommune, Inc.NYSE: EVMN

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $349K fell 7.4% year over year. Sequentially, it rose 7.1% from the prior quarter.

Context

  • Depreciation & amortization amounted to 10.7% of revenue in FY2025, down 7.7 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$349K+7.1% QoQ
Last fiscal yearDec 2025
$1.39M+7.9% YoY
LTMMar 2026
$1.36M— YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.4%——
1 year+7.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
1.39M USD
Year-over-year change
+7.9%
2-year CAGR
+17.9%

Depreciation & Amortization vs competitors

How EVMN compares with its peers on the latest reported figures

  • EVMN's LTM Mar 2026 depreciation & amortization of $1.36M is the 8th highest of the 10 companies compared; the peer median is $8.21M.
  • Depreciation & amortization amounts to 13.6% of revenue for EVMN, versus a peer median of 11.0%.
EVMN Competitors Peer median
Depreciation & Amortization for EVMN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FTREFortrea Holdings Inc.LTM Jun 2026$78.3M -3.5%-5.9%2.9%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$34.32M -1.7%-8.0%11.8%
OABIOmniAb, Inc.LTM Mar 2026$23.01M -1.6%+6.0%79.6%
CDXSCodexis, Inc.LTM Mar 2026$8.57M +6.1%-1.0%11.0%
ZYMEZymeworks Inc.LTM Sep 2026$8.21M -35.8%-2.5%3.1%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$2.64M +6.6%+30.9%—
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$2.45M +41.2%-1.9%32.1%
EVMNEvommune, Inc.LTM Mar 2026$1.36M ——13.6%
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$187K -43.8%-21.9%0.1%
CLYMClimb Bio, Inc.LTM Mar 2026$135K ———
Peer median (excluding EVMN) $8.21M-1.6%-2.2%11.0%

Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5M7M13M
Cost of Revenue1M1.29M0
Gross Profit4M5.71M13M
Gross Margin80.0%81.6%100.0%
Research & Development32M64.24M74.04M
Selling, General & Admin9.85M11.48M20.03M
Operating Expenses41.85M75.73M94.07M
Depreciation & Amortization1M1.29M1.39M
EBITDA(33M)(65.49M)(67.48M)
EBITDA Margin-659.9%-935.5%-519.1%
Operating Income(37.85M)(70.01M)(81.07M)
Operating Margin-757.0%-1000.2%-623.6%
Interest Income3.86M3.24M3.32M
Interest Expense58K34K0
Other Income / Expenses3.8M3.2M12.2M
Income Before Tax(34.05M)(66.81M)(68.87M)
Pre-Tax Margin-681.1%-954.4%-529.8%
Income Tax Expense000
Net Income(34.05M)(66.81M)(68.87M)
Net Margin-681.1%-954.4%-529.8%
EPS (Basic)(1.13)(2.27)(2.18)
EPS (Diluted)(1.13)(2.27)(2.18)
Weighted Avg Shares30.08M30.08M31.52M
Weighted Avg Shares (Diluted)30.08M30.08M31.52M

Evommune, Inc.

NYSE:EVMN

Intrinsic Alpha fair value

Locked

Current Price

$6.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.